Monitor for any amendment to this 8-K under Item 1.05 if the company later determines a material impact. Also watch for regulatory notifications, potential patient lawsuits, or reputational effects, though current disclosure suggests limited exposure.
NVCR drugs
NVCR drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+20- T+0 · Sep 1 $17.38entry
- T+1 · 3mo ago +2.59%α +2.15% · $17.83
- T+5 · 2mo ago −10.07%α −10.15% · $15.63
- T+20 · 7w ago −7.91%α −9.09% · $16.01
- T+53 · todayOpen
- T+60 · in 8d Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
NovoCure disclosed a cybersecurity incident from mid-August 2026 involving unauthorized access to some information systems. Exposed data includes internal patient ID numbers for over 1,400 U.S. records (no names), fewer than 50 patients with additional identifying information, and general contact info for healthcare providers and employees. The company states no access to medical devices, operations are fully functional, and it does not believe the incident will have a material financial impact.
Key Facts
- Unauthorized access detected mid-August 2026; containment and investigation initiated with independent forensic experts.
- Exposed data: internal patient ID numbers for over 1,400 U.S. patient records (no names or other identifying data).
- Patient data for fewer than 50 patients in the western U.S. with additional identifying information was exposed.
- General contact information for healthcare providers and NovoCure employees (job titles, phone numbers) was exposed.
- No access to medical treatment devices; all systems fully functional; operations not compromised.
- Company does not believe the incident will have a material impact on financial condition or results of operations at this time.
Financial Impact
No material financial impact expected per company; incident-related costs not disclosed.
Risk Factors
- Potential regulatory fines or enforcement actions from HIPAA or other privacy regulators.
- Risk of class-action litigation from affected patients, especially the fewer than 50 with additional identifying data.
- Reputational damage could impact provider relationships or patient trust in the long term.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 8 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (NVCR), Batch item 1 | 0001645113-26-000065 |
| Document: 0001645113-26-000065-index-headers.html | 0001645113-26-000065 |
| Document: 0001645113-26-000065-index.html | 0001645113-26-000065 |
| Document: 0001645113-26-000065.txt | 0001645113-26-000065 |
| 8-K Filing (NVCR), Batch item 5 | 0001645113-26-000065 |
| Document: 0001645113-26-000065-index-headers.html | 0001645113-26-000065 |
| Document: 0001645113-26-000065-index.html | 0001645113-26-000065 |
| Document: 0001645113-26-000065.txt | 0001645113-26-000065 |
Track record
20 reports on NVCR
5 of 7 bullish or bearish reports moved the stock their way by T+1. Best: +19.75% at T+20 after the Feb 27, 2026 report. 5 of 7 went positive at some point.
Filters
- Nov 12, 20264d ago Insider Cluster Neutral 2/10 Entry $11.83 to $11.30 Now $11.30 −4.48% ▼ −4.48% −2.57% vs SPY
- Nov 9, 20267d ago SC 13G/A Neutral 3/10 Entry $11.81 to $11.99 Now $11.30 −4.32% ▲ +1.52% +0.21% vs SPY
- Nov 9, 20267d ago 144 Neutral 2/10 Entry $11.81 to $11.99 Now $11.30 −4.32% ▲ +1.52% +0.21% vs SPY
- Nov 9, 20267d ago 8-K Bearish 6/10 Entry $12.53 to $11.81 Now $11.30 +9.82% ▲ +5.75% +5.38% vs SPY
- Oct 29, 202618d ago 8-K Bullish 6/10 Entry $13.11 to $13.15 Now $11.30 −13.81% ▲ +0.31% +2.08% vs SPY
- Oct 1, 20266w ago 8-K Bullish 6/10 Entry $15.92 to $14.94 Now $11.30 −29.02% ▼ −6.16% −6.90% vs SPY
- Sep 9, 20269w ago 8-K Neutral 2/10 Entry $15.63 to $15.35 Now $11.30 −27.70% ▼ −1.79% −1.19% vs SPY
- Sep 1, 202610w ago 8-K Neutral 3/10 Viewing Entry $17.38 to $17.83 Now $11.30 −34.98% ▲ +2.59% +2.15% vs SPY
- Jul 23, 202616w ago 8-K Bullish 7/10 Entry $19.99 to $17.65 Now $11.30 −43.47% ▼ −11.71% −11.81% vs SPY
- Jun 30, 202619w ago 8-K Bullish 7/10 Entry $15.15 to $15.78 Now $11.30 −25.41% ▲ +4.16% +4.29% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers